azathioprine has been researched along with methyldopa in 17 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (23.53) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (23.53) | 29.6817 |
2010's | 9 (52.94) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Claman, HN; Karr, RM; Kohler, PF; Mass, MF; McIntosh, RM; Sams, WM; Small, P; Stanford, RE; Thorne, EG | 1 |
Anderson, CF; Kuster, G; Weiland, LH; Wilkowske, CJ; Woods, JE | 1 |
Beaudry, C; Laplate, L | 1 |
Datko, LJ; Kassarich, J; Rosenthale, ME; Schneider, F | 1 |
1 review(s) available for azathioprine and methyldopa
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for azathioprine and methyldopa
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Systemic (allergic?) vasculitis.
Topics: Antigen-Antibody Complex; Azathioprine; Complement System Proteins; Creatinine; Diphenhydramine; Erythrocytes; Female; Fluorescent Antibody Technique; Humans; Hypertension; Immune Complex Diseases; Inflammation; Kidney Diseases; Kidney Glomerulus; Methyldopa; Microscopy, Electron; Middle Aged; Necrosis; Prednisone; Proteinuria; Skin; Skin Manifestations; Urine; Vascular Diseases | 1974 |
Plasma cell lymphoma after renal transplantation.
Topics: Adult; Age Factors; Antacids; Antilymphocyte Serum; Azathioprine; Hepatitis A; Humans; Injections, Subcutaneous; Intestinal Neoplasms; Kidney Transplantation; Male; Methyldopa; Methylprednisolone; Plasmacytoma; Time Factors; Transplantation, Homologous | 1972 |
Treatment of renal failure from diabetic nephropathy with cadaveric homograft.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Cadaver; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Retinopathy; Graft Rejection; Humans; Insulin, Long-Acting; Kidney Failure, Chronic; Kidney Transplantation; Male; Methods; Methyldopa; Prednisone; Transplantation, Homologous; Visual Acuity | 1973 |
Chemotherapy of experimental allergic encephalomyelitis (EAE).
Topics: Allopurinol; Aminocaproates; Analgesics; Animals; Antineoplastic Agents; Azathioprine; Body Weight; Chloroquine; Colchicine; Cortisone; Cyclophosphamide; Cyproheptadine; Diazoxide; Dimethyl Sulfoxide; Encephalomyelitis, Autoimmune, Experimental; Hydrocortisone; Immunosuppressive Agents; Male; Mercaptopurine; Methotrexate; Methyldopa; Nialamide; Oils; Organ Size; Rats; Strychnine; Talc; Thalidomide; Thioguanine; Thiomalates | 1969 |